Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

671 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cardiovascular risk factors and dementia.
Fillit H, Nash DT, Rundek T, Zuckerman A. Fillit H, et al. Am J Geriatr Pharmacother. 2008 Jun;6(2):100-18. doi: 10.1016/j.amjopharm.2008.06.004. Am J Geriatr Pharmacother. 2008. PMID: 18675769 Review.
BACKGROUND: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a significant economic burden. ...METHODS: We conducted a review of the literature for the simultaneous presence of 2 major topics, cardio …
BACKGROUND: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a sig …
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Frishman WH, Zuckerman AL. Frishman WH, et al. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):675-81. doi: 10.1586/14779072.2.5.675. Expert Rev Cardiovasc Ther. 2004. PMID: 15350169 Review.
Unfortunately, less than a third of patients with both conditions are identified, and fewer than one in ten reach the treatment goals for both factors. ...Amlodipine/atorvastatin retains the safety and efficacy of its parent compounds whilst simplifying the management of t …
Unfortunately, less than a third of patients with both conditions are identified, and fewer than one in ten reach the treatment goals …
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators. Bangalore S, et al. Eur Heart J. 2010 Dec;31(23):2897-908. doi: 10.1093/eurheartj/ehq328. Epub 2010 Sep 16. Eur Heart J. 2010. PMID: 20846991 Clinical Trial.
A time-dependent, non-linear, multivariate Cox proportional hazard model identified a nadir of 146.3/81.4 mmHg where the event rate was lowest. A similar non-linear relationship with a higher risk of events at lower pressures was found for most of the
A time-dependent, non-linear, multivariate Cox proportional hazard model identified a nadir of 146.3/81.4 mmHg where the event
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators. Koren MJ, et al. Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11. Am J Kidney Dis. 2009. PMID: 19216014 Clinical Trial.
INTERVENTION: Focused atorvastatin therapy to a low-density lipoprotein cholesterol goal of less than 80 mg/dL or maximum dose of 80 mg/d versus usual care as deemed appropriate by patients' regular physicians. ...RESULTS: At baseline, 579 patients (23.7%) had CKD: 31.6% o …
INTERVENTION: Focused atorvastatin therapy to a low-density lipoprotein cholesterol goal of less than 80 mg/dL or maximum dose of 80 …
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Epstein M, Leary E, Laskey R, Zuckerman A, Reed D, Lowe W. Epstein M, et al. J Cardiometab Syndr. 2007 Summer;2(3):163-7. doi: 10.1111/j.1559-4564.2007.07295.x. J Cardiometab Syndr. 2007. PMID: 17786079 Clinical Trial.
These data indicate that in this patient population, atorvastatin, even at a high dose, does not interfere with renal tubular reabsorption of protein, induce renal tubular dysfunction, or alter glomerular filtration rate in humans....
These data indicate that in this patient population, atorvastatin, even at a high dose, does not interfere with renal tubular reabsor …
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Shepherd J, et al. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. doi: 10.2215/CJN.04371206. Epub 2007 Oct 17. Clin J Am Soc Nephrol. 2007. PMID: 17942759 Clinical Trial.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 10,001 patients with coronary heart disease and LDL cholesterol levels of <130 mg/dl were randomly assigned to double-blind therapy with 10 or 80 mg/d atorvastatin. ...
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 10,001 patients with coronary heart disease and LDL cholesterol levels …
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li H, Schulman SL, Raber S, Zuckerman A, Isaacs JD. Kremer JM, et al. Arthritis Res Ther. 2015 Apr 6;17(1):95. doi: 10.1186/s13075-015-0612-7. Arthritis Res Ther. 2015. PMID: 25889308 Free PMC article. Clinical Trial.
METHODS: This was a randomised, placebo-controlled, Phase 1 study (NCT01484561). Patients were aged ≥18 years with active RA. ...A reduction of 8% (90% confidence interval [CI]: 2%, 14%) from baseline in adjusted geometric mean mGFR was observed during tofacitinib t …
METHODS: This was a randomised, placebo-controlled, Phase 1 study (NCT01484561). Patients were aged ≥18 years with active RA. ...A
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Shepherd J, et al. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072. J Am Coll Cardiol. 2008. PMID: 18402899 Clinical Trial.
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with CKD. METHODS: A total of 10,001 patients with CHD were randomized to double-blind therapy with atorvastatin 80 mg/day or 10 mg/day. ...After a median follow-up of …
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with CKD. METHODS: A total of 10,00 …
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, Geier J, Kwok K, Riese R. Charles-Schoeman C, et al. Semin Arthritis Rheum. 2016 Dec;46(3):261-271. doi: 10.1016/j.semarthrit.2016.05.014. Epub 2016 Jun 2. Semin Arthritis Rheum. 2016. PMID: 27443588
CV events, including major adverse CV events (MACE: CV death and non-fatal CV events) and congestive heart failure (CHF), were assessed by a blinded adjudication committee. ...CONCLUSIONS: Tofacitinib was associated with a low incidence of CV events in a larg …
CV events, including major adverse CV events (MACE: CV death and non-fatal CV events) and congestive heart failure (CHF), were assessed by …
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R. Charles-Schoeman C, et al. Semin Arthritis Rheum. 2016 Aug;46(1):71-80. doi: 10.1016/j.semarthrit.2016.03.004. Epub 2016 Mar 9. Semin Arthritis Rheum. 2016. PMID: 27079757 Review.
Alterations in non-traditional lipid assessments, such as high-density lipoprotein (HDL) function and HDL-associated proteins, have been described in patients with active RA, including elevated HDL-associated serum amyloid A and decreased paraoxonase-1 activity. ...In addi …
Alterations in non-traditional lipid assessments, such as high-density lipoprotein (HDL) function and HDL-associated proteins, have been des …
671 results
Jump to page
Feedback